Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Content from other channels on our network

Flow control for optimising growth of microorganisms

Funding boost to cut cotton industry's emissions

Aust partnership leads to solar-powered canola

Making the national electricity market fit for purpose

Driving progress in clean energy

Over-the-air vulnerabilities discovered in Advantech EKI access points

Tasmanian Government seeks input on advanced technology strategy

CSIRO electrolyser pilot a success at Bluescope Steel

Three states announce BESS projects in a week

Emerson offers solution to reduce energy costs and emissions

Making Australian canola oil more sustainable with solar power

Who will pay for emission reductions in the milk sector?

Fonterra charts progress against its 'Climate Roadmap'

How to manage safety risks in the low-moisture food sector?

Pure Dairy appoints new CCO